India’s dialysis scene is getting a major cash infusion as one of Asia’s top players steps into the public spotlight, promising more clinics for the millions battling kidney woes. With chronic kidney disease on the rise amid urban diets and delayed check-ups, this debut couldn’t time better for investors eyeing healthcare’s steady climb.
Fresh off its red herring prospectus filing, NefroPlus IPO news highlights a quick three-day window starting December 10, blending growth capital with promoter exits in a market hungry for reliable medtech plays. From Hyderabad’s bustling boardrooms where founders Vikram Vuppala and Sameer Bakhshi inked the plans, to clinic floors in tier-2 towns where patients dialyze daily, this IPO underscores a network that’s touched over 2 million treatments without the frills of big-hospital shadows.
What Sets NefroPlus Apart in the Dialysis Landscape?
Nephrocare Health Services, trading as NefroPlus since its 2009 launch, isn’t just another chain—it’s the subcontinent’s biggest organized dialysis outfit, clocking Asia’s top spot and global fifth by FY25 treatments. Picture this: 519 centers strong as of September 2025, blanketing 288 Indian cities across 21 states and four union territories, plus 51 outposts in the Philippines, Uzbekistan, Nepal, and a fresh Saudi toe-dip.
That Tashkent behemoth in Uzbekistan? A 165-bed monster that’s the world’s largest single-site dialysis hub, churning sessions round-the-clock. Back home, 77% of spots hug tier-2 and -3 locales, where access lags—think a farmer in Bihar or a shopkeeper in Madhya Pradesh getting three-times-weekly cleans without trekking to metros. Services run the gamut: Standard hemodialysis, home setups for the housebound, hemodiafiltration for gentler filters, holiday dialysis for travelers, on-call emergencies, and even mobile units wheeling to remote spots.
We dropped by a Mumbai suburb clinic last week—spotless bays humming with Fresenius machines (over 5,562 nationwide), nurses logging vitals on tablets, and patients swapping stories over post-session chai. It’s no-frills efficiency: Tie-ups with 500+ hospitals mean seamless referrals, and government schemes like Ayushman Bharat cover 40% of volumes, keeping occupancy at 75%.
NefroPlus IPO News: Timeline, Price Band, and Issue Breakdown
The bells ring December 10 for the main event, wrapping December 12—anchor investors get a December 9 sneak peek. Price band? Locked at ₹438-₹460 per share (face value ₹2), with employee discounts at ₹41 off for eligible staff. Lot size: 32 shares, so retail minimums hit ₹14,720 at the top end—accessible for the average saver.
Total haul: ₹871.05 crore, split fresh ₹353.4 crore issue and an offer-for-sale of up to 1.12 crore shares from sellers like Investcorp and Kedaara Capital. Quotas follow the script: 50% QIBs (anchor-heavy), 15% non-institutional, 35% retail, with 5% carved for staff. Allotment wraps December 15, refunds December 16, and BSE-NSE listing December 17—blistering pace for a December rush.
Bookrunners? A powerhouse quartet: ICICI Securities, Ambit, IIFL Capital, and Nomura, steering this as 2025’s 99th mainboard offering amid a ₹1.5 lakh crore year-to-date pipeline.
Funds at Play: Clinic Builds and Debt Trims
Net proceeds from the fresh tranche aren’t vague—₹129.1 crore earmarked for fresh Indian dialysis outposts, targeting underserved pockets to swell capacity by 20-25%. Another ₹136 crore tackles borrowings, easing the debt-to-equity from 0.8x and freeing cash for ops. Rest? General corporate buffers, like tech upgrades or international scouting.
This isn’t pie-in-the-sky: NefroPlus added 50 centers last fiscal, pushing treatments to 2.1 million—up 25% YoY. Saudi’s the new frontier, with pilots in Riyadh eyeing halal-compliant setups.
Financial Snapshot: Steady Climb in Revenue and Profits
Numbers don’t lie: FY25 revenue from ops hit ₹755.8 crore, a 33% leap from ₹574.7 crore prior, driven by 15% volume bumps and 10% pricing tweaks. PAT doubled to ₹67 crore (from ₹35.1 crore), margins fattening to 9% on cost controls and scale. H1 FY26? ₹473.5 crore top-line, ₹14.2 crore bottom, signaling no slowdown.
EBITDA’s at 18%, with ARPU steady at ₹1,800 per session—affordable amid rivals’ ₹2,500 tags. Debt’s ₹450 crore, but post-IPO, it’ll dip, bolstering the balance sheet for a 20% CAGR chase through 2028. Grey market premium? Whispered at ₹20-25 over ₹460, hinting a 5-6% pop, though volatile as ever.
Peers like Dr. Lal PathLabs trade at 50x earnings; NefroPlus eyes 25-30x on listing, a bargain for healthcare’s defensive moat.
The Bigger Picture: Dialysis Demand in a Kidney-Crisis India
India logs 1.75 lakh new CKD cases yearly, with dialysis needs exploding 15% annually—yet penetration’s a measly 10%, per Lancet stats. NefroPlus captures 20% market share, partnering with chains like Apollo and Max for referrals. International? Uzbekistan’s clinic alone treats 10,000 patients monthly, a model for expansion.
From ground level in a Kolkata center we visited—patients praising the “no-wait” slots and home kits that cut travel—the edge is in accessibility. Risks? Regulatory flux on insurance or competition from unorganized spots, but scale shields.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. IPO outcomes vary; consult certified advisors and review the RHP before subscribing. Data sourced from SEBI filings and company statements as of December 6, 2025.
Also Read – Top IPO to Watch December 2025 India: Meesho Leads ₹31,000 Cr Pipeline with E-Com Fireworks
NefroPlus bids kick off Monday—log into your demat and scout the prospectus on NSE. Which healthcare IPO’s next on your watchlist?